Owl Peak Labs

Executive Summary

Owl Peak Labs is a San Diego-based diagnostics company developing SpectraGI, a revolutionary thermal imaging system for early detection of colorectal cancer. By identifying metabolic heat patterns in the gastrointestinal tract, SpectraGI aims to detect precancerous and cancerous tissue at the earliest, most treatable stage. Colorectal cancer is the third most common cancer worldwide, and current screening methods like colonoscopy are invasive, costly, and have limited compliance. Owl Peak's non-invasive, radiation-free approach could dramatically improve screening rates and outcomes. Founded in 2017, the company is privately held and has not disclosed funding or valuation. While still in development, SpectraGI addresses a significant unmet need in oncology diagnostics. The technology leverages metabolic heat signatures—a novel biomarker—to differentiate malignant from benign tissue, potentially offering higher sensitivity and specificity than traditional methods. If successful, Owl Peak Labs could disrupt the colorectal cancer screening market, currently dominated by invasive procedures and stool-based tests. The company's progress toward regulatory approval and clinical validation will be key to its trajectory.

Upcoming Catalysts (preview)

• Q3 2026Completion of pivotal clinical trial for SpectraGI70% success
• Q4 2025FDA Breakthrough Device designation or pre-submission meeting60% success
• Q2 2026Strategic partnership or licensing deal for commercialization50% success